{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T01:24:30Z","timestamp":1783819470213,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["High Blood Press Cardiovasc Prev"],"DOI":"10.1007\/s40292-024-00664-y","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:21:56Z","timestamp":1724408516000},"page":"485-492","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vericiguat on C-reactive Protein Level and Prognosis in Patients with Hypertensive Heart Failure"],"prefix":"10.1007","volume":"31","author":[{"given":"Yabing","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"173","key":"664_CR1","first-page":"171","volume":"34","author":"JC He","year":"2022","unstructured":"He JC, WuY, Wang YD. The independent association between age and serum cholesterol levels in patients with familial hypercholesterolemia. Discov Med. 2022;34(173):171\u201380.","journal-title":"Discov Med"},{"issue":"4","key":"664_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.hfc.2019.06.007","volume":"15","author":"J Slivnick","year":"2019","unstructured":"Slivnick J, Lampert BC. Hypertension and heart failure. Heart Fail Clin. 2019;15(4):531\u201341.","journal-title":"Heart Fail Clin"},{"issue":"2","key":"664_CR3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ccl.2021.12.011","volume":"40","author":"KE Di Palo","year":"2022","unstructured":"Di Palo KE, Barone NJ. Hypertension and heart failure: prevention, targets, and treatment. Cardiol Clin. 2022;40(2):237\u201344.","journal-title":"Cardiol Clin"},{"issue":"36","key":"664_CR4","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","volume":"42","author":"AM Jackson","year":"2021","unstructured":"Jackson AM, Jhund PS, Anand IS, D\u00fcngen HD, Lam CSP, Lefkowitz MP, Linssen G, Lund LH, Maggioni AP, Pfeffer MA, Rouleau JL, Saraiva JFK, Senni M, Vardeny O, Wijkman MO, Yilmaz MB, Saito Y, Zile MR, Solomon SD, McMurray JJV. Sacubitril-Valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42(36):3741\u201352.","journal-title":"Eur Heart J"},{"issue":"22","key":"664_CR5","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.jacc.2020.10.007","volume":"76","author":"BA Maron","year":"2020","unstructured":"Maron BA, Kovacs G, Vaidya A, Bhatt DL, Nishimura RA, Mak S, Guazzi M, Tedford RJ. Cardiopulmonary hemodynamics in pulmonary hypertension and heart failure: JACC review topic of the week. J Am Coll Cardiol. 2020;76(22):2671\u201381.","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"664_CR6","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","volume":"382","author":"PW Armstrong","year":"2020","unstructured":"Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J, Lam CSP, PonikowskiP, Voors AA, Jia G, McNulty SE, Patel MJ, Roessig L, Koglin J, O\u2019Connor CM, VICTORIA Study Group. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883\u201393.","journal-title":"N Engl J Med"},{"issue":"5","key":"664_CR7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s10557-020-07099-2","volume":"35","author":"A Aimo","year":"2021","unstructured":"Aimo A, Pateras K, Stamatelopoulos K, Bayes-Genis A, Lombardi CM, Passino C, Emdin M, Georgiopoulos G. Relative efficacy of sacubitril-valsartan, vericiguat, and SGLT2 inhibitors in heart failure with reduced ejection fraction: a systematic review and network meta-analysis. Cardiovasc Drugs Ther. 2021;35(5):1067\u201376.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"5","key":"664_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jchf.2022.12.014","volume":"11","author":"J Butler","year":"2023","unstructured":"Butler J, Zheng Y, Khan MS, Bonderman D, Lund LH, deFilippi CR, Blaustein RO, Ezekowitz JA, Freitas C, Hernandez AF, O\u2019Connor CM, Voors AA, Westerhout CM, Lam CSP, Armstrong PW, VICTORIA Study Group. Ejection fraction, biomarkers, and outcomes and impact of vericiguat on outcomes across EF in VICTORIA. JACC Heart Fail. 2023;11(5):583\u201392.","journal-title":"JACC Heart Fail"},{"issue":"10","key":"664_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11886-021-01580-6","volume":"23","author":"CM Lombardi","year":"2021","unstructured":"Lombardi CM, Cimino G, Pagnesi M, Dell\u2019Aquila A, Tomasoni D, Ravera A, Inciardi R, Carubelli V, Vizzardi E, Nodari S, Emdin M, Aimo A. Vericiguat for heart failure with reduced ejection fraction. CurrCardiol Rep. 2021;23(10):144.","journal-title":"CurrCardiol Rep"},{"issue":"3","key":"664_CR10","first-page":"437","volume":"36","author":"ML Yao","year":"2022","unstructured":"Yao ML, Liu J, Pan BY, Yu HT, Bao N. Prevention and treatment of fluid overload in bipolar hysteroscopy. J Biol Regulat Homeost Agent. 2022;36(3):437\u201344.","journal-title":"J Biol Regulat Homeost Agent"},{"issue":"1","key":"664_CR11","first-page":"45","volume":"56","author":"O Eschen","year":"2010","unstructured":"Eschen O, Christensen JH, Rovere LA, Romano MT, Sala P, Schmidt P. Effects of marine n-3 fatty acids on circulating levels of soluble adhesion molecules in patients with chronic heart failure. Cell Mol Biol (Noisy-le-grand). 2010;56(1):45\u201351.","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"8","key":"664_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.4049\/immunohorizons.1900026","volume":"3","author":"B Vulesevic","year":"2019","unstructured":"Vulesevic B, Lavoie SS, Neagoe PE, Dumas E, R\u00e4kel A, White M, Sirois MG. CRP induces NETosis in heart failure patients with or without diabetes. Immunohorizons. 2019;3(8):378\u201388.","journal-title":"Immunohorizons"},{"issue":"4","key":"664_CR13","first-page":"2947","volume":"13","author":"Q Wang","year":"2021","unstructured":"Wang Q, An Y, Wang H, Zhang N, Deng S. The clinical significance of changes in cTnT, CRP and NT-proBNP levels in patients with heart failure. Am J Transl Res. 2021;13(4):2947\u201354.","journal-title":"Am J Transl Res"},{"issue":"5","key":"664_CR14","first-page":"277","volume":"64","author":"F Kumase","year":"2010","unstructured":"Kumase F, Morizane Y, Mohri S, Takasu I, Ohtsuka A, Ohtsuki H. Glycocalyx degradation in retinal and choroidal capillary endothelium in rats with diabetes and hypertension. Acta Med Okayama. 2010;64(5):277\u201383.","journal-title":"Acta Med Okayama"},{"issue":"2","key":"664_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41569-021-00605-5","volume":"19","author":"G Savarese","year":"2022","unstructured":"Savarese G, Stolfo D, Sinagra G, Lund LH. Heart failure with mid-range or mildly reduced ejection fraction. Nat Rev Cardiol. 2022;19(2):100\u201316.","journal-title":"Nat Rev Cardiol"},{"issue":"18","key":"664_CR16","doi-asserted-by":"publisher","first-page":"6483","DOI":"10.3390\/ijms21186483","volume":"21","author":"N Latic","year":"2020","unstructured":"Latic N, Erben RG. Vitamin D and cardiovascular disease, with emphasis on hypertension, atherosclerosis, and heart failure. Int J Mol Sci. 2020;21(18):6483.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"664_CR17","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1002\/ejhf.1629","volume":"21","author":"G Hao","year":"2019","unstructured":"Hao G, Wang X, Chen Z, Zhang L, Zhang Y, Wei B, Zheng C, Kang Y, Jiang L, Zhu Z, Zhang J, Wang Z, Gao R. China Hypertension Survey investigators. Prevalence of heart failure and left ventricular dysfunction in China: China Hypertension Survey, 2012\u20132015. Eur J Heart Fail. 2019;21(11):1329\u201337.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"664_CR18","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11906-020-01093-7","volume":"22","author":"HE Hicklin","year":"2020","unstructured":"Hicklin HE, Gilbert ON, Ye F, Brooks JE, Upadhya B. Hypertension as a road to treatment of heart failure with preserved ejection fraction. Curr Hypertens Rep. 2020;22(10):82.","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"664_CR19","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1001\/jamacardio.2020.6455","volume":"6","author":"CSP Lam","year":"2021","unstructured":"Lam CSP, Giczewska A, Sliwa K, Edelmann F, Refsgaard J, Bocchi E, Ezekowitz JA, Hernandez AF, O\u2019Connor CM, Roessig L, Patel MJ, Pieske B, Anstrom KJ, Armstrong PW, VICTORIA Study Group. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial. JAMA Cardiol. 2021;6(6):706\u201312.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"664_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.rce.2021.12.005","volume":"222","author":"JR Gonz\u00e1lez-Juanatey","year":"2022","unstructured":"Gonz\u00e1lez-Juanatey JR, Anguita-S\u00e1nchez M, Bayes-Gen\u00eds A, Com\u00edn-Colet J, Garc\u00eda-Quintana A, Recio-Mayoral A, Zamorano-G\u00f3mez JL, Cepeda-Rodrigo JM, Manzano L. Vericiguat in heart failure: from scientific evidence to clinical practice. Rev Clin Esp (Barc). 2022;222(6):359\u201369.","journal-title":"Rev Clin Esp (Barc)"},{"key":"664_CR21","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2147\/TCRM.S357422","volume":"18","author":"H Kassis-George","year":"2022","unstructured":"Kassis-George H, Verlinden NJ, Fu S, Kanwar M. Vericiguat in heart failure with a reduced ejection fraction: patient selection and special considerations. Ther Clin Risk Manag. 2022;18:315\u201322.","journal-title":"Ther Clin Risk Manag"},{"key":"664_CR22","first-page":"175394471987008","volume":"13","author":"S Giannitsi","year":"2019","unstructured":"Giannitsi S, Bougiakli M, Bechlioulis A, Kotsia A, Michalis LK, Naka KK. 6-minute walking test: a useful tool in the management of heart failure patients. TherAdvCardiovasc Dis. 2019;13:1753944719870084.","journal-title":"TherAdvCardiovasc Dis"},{"issue":"3","key":"664_CR23","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1161\/HYPERTENSIONAHA.121.17440","volume":"78","author":"K Kario","year":"2021","unstructured":"Kario K, Williams B. Nocturnal hypertension and heart failure: mechanisms, evidence, and new treatments. Hypertension. 2021;78(3):564\u201377.","journal-title":"Hypertension"},{"issue":"6","key":"664_CR24","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.healun.2022.02.016","volume":"41","author":"F Castagna","year":"2022","unstructured":"Castagna F, McDonnell BJ, Mondellini GM, Gaudig A, Pinsino A, McEniery C, St\u00f6hr EJ, Takeda K, Naka Y, Uriel N, Yuzefpolskaya M, Cockcroft J, Parati G, Colombo PC. Twenty-four-hour blood pressure and heart rate variability are reduced in patients on left ventricular assist device support. J Heart Lung Transpl. 2022;41(6):802\u20139.","journal-title":"J Heart Lung Transpl"},{"issue":"7","key":"664_CR25","first-page":"802","volume":"45","author":"L Liang","year":"2022","unstructured":"Liang L, Huang L, Zhao X, Zhao L, Tian P, Huang B, Feng J, Zhang J, Zhang Y. Prognostic value of RDW alone and in combination with NT-proBNP in patients with heart failure. ClinCardiol. 2022;45(7):802\u201313.","journal-title":"ClinCardiol"},{"issue":"6","key":"664_CR26","doi-asserted-by":"publisher","first-page":"5081","DOI":"10.1002\/ehf2.13576","volume":"8","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Pharithi RB, Kerr B, Ryan C, Ryan F, Collins L, Halley C, Barrett M, Watson CJ, McDonald K, Ledwidge M. NT-proBNP\/BNP ratio for prognostication in European caucasian patients enrolled in a heart failure prevention programme. ESC Heart Fail. 2021;8(6):5081\u201391.","journal-title":"ESC Heart Fail"},{"issue":"7","key":"664_CR27","doi-asserted-by":"publisher","first-page":"7970","DOI":"10.21037\/apm-21-1361","volume":"10","author":"X Yang","year":"2021","unstructured":"Yang X, Xing Y, Li K. Changes in clinical biochemical indexes of patients with heart failure with preserved ejection fraction or patients with hypertensive heart disease before and after treadmill exercise. Ann Palliat Med. 2021;10(7):7970\u20136.","journal-title":"Ann Palliat Med"},{"issue":"7","key":"664_CR28","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.jchf.2022.03.004","volume":"10","author":"JD Smeijer","year":"2022","unstructured":"Smeijer JD, Koomen J, Kohan DE, McMurray JJV, Bakris GL, Correa-Rotter R, Hou FF, JanuzziJL, Kitzman DW, Kolansky DM, Makino H, Perkovic V, Tobe S, Parving HH, de Zeeuw D, Heerspink HJL. Increase in BNP in response to endothelin-receptor antagonist atrasentan is associated with incidentheartfailure. JACC Heart Fail. 2022;10(7):498\u2013507.","journal-title":"JACC Heart Fail"},{"key":"664_CR29","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.peptides.2018.10.002","volume":"111","author":"T Miyauchi","year":"2019","unstructured":"Miyauchi T, Sakai S. Endothelin and the heart in health and diseases. Peptides. 2019;111:77\u201388.","journal-title":"Peptides"},{"issue":"7","key":"664_CR30","doi-asserted-by":"publisher","first-page":"e16695","DOI":"10.2196\/16695","volume":"8","author":"P Indraratna","year":"2020","unstructured":"Indraratna P, Tardo D, Yu J, Delbaere K, Brodie M, Lovell N, Ooi SY. Mobile phone technologies in the management of ischemic heart disease, heart failure, and hypertension: systematic review and meta-analysis. JMIR MhealthUhealth. 2020;8(7):e16695.","journal-title":"JMIR MhealthUhealth"},{"issue":"6","key":"664_CR31","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1053\/j.jvca.2020.07.016","volume":"35","author":"PS Pagel","year":"2021","unstructured":"Pagel PS, Tawil JN, Boettcher BT, Izquierdo DA, Lazicki TJ, Crystal GJ, Freed JK. Heart failure with preserved ejection fraction: a comprehensive review and update of diagnosis, pathophysiology, treatment, and perioperative implications. J Cardiothorac Vasc Anesth. 2021;35(6):1839\u201359.","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"1","key":"664_CR32","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12872-022-02610-z","volume":"22","author":"K Frans\u00e9n","year":"2022","unstructured":"Frans\u00e9n K, Pettersson C, Hurtig-Wennl\u00f6f A. CRP levels are significantly associated with CRP genotype and estrogen use in the lifestyle, biomarker and atherosclerosis (LBA) study. BMC Cardiovasc Disord. 2022;22(1):170.","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"664_CR33","doi-asserted-by":"publisher","first-page":"e024999","DOI":"10.1161\/JAHA.121.024999","volume":"11","author":"S Selvaraj","year":"2022","unstructured":"Selvaraj S, Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Juliano RA, Jiao L, Tardif JC, Ballantyne CM, REDUCE-IT Investigators. Impact of icosapent ethyl on cardiovascular risk reduction in patients with heart failure in REDUCE-IT. J Am Heart Assoc. 2022;11(7):e024999.","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"664_CR34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.hjc.2018.08.006","volume":"61","author":"G Zhao","year":"2020","unstructured":"Zhao G, Zhang H, Wang Y, Gao X, Liu H, Liu W. Effects of levocarnitine on cardiac function, urinary albumin, hs-CRP, BNP, and troponin in patients with coronary heart disease and heart failure. Hellenic J Cardiol. 2020;61(2):99\u2013102.","journal-title":"Hellenic J Cardiol"},{"issue":"5","key":"664_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41569-019-0315-x","volume":"17","author":"L Adamo","year":"2020","unstructured":"Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17(5):269\u201385.","journal-title":"Nat Rev Cardiol"}],"container-title":["High Blood Pressure & Cardiovascular Prevention"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-024-00664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40292-024-00664-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40292-024-00664-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:07:13Z","timestamp":1729098433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40292-024-00664-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["664"],"URL":"https:\/\/doi.org\/10.1007\/s40292-024-00664-y","relation":{},"ISSN":["1179-1985"],"issn-type":[{"value":"1179-1985","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"27 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committee of Xingtai Third Hospital (Ethical Approval number: XTH-21-324 and clinical trial number: CT324). All the included subjects and their families were informed of the content of this study and signed informed consent to participate in the study. All experiments were performed in accordance with relevant guidelines and regulations such as the Declaration of Helsinki and the patients signed the informed consent form and agreed to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}